Join Growin Stock Community!

Burning rock biotech limitedBNR.US Overview

US StockHealthcare
(No presentation for BNR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BNR AI Insights

BNR Overall Performance

BNR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BNR Recent Performance

1.70%

Burning rock biotech limited

0.05%

Avg of Sector

-0.31%

S&P500

BNR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BNR Key Information

BNR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BNR Profile

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.

Price of BNR

BNR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BNR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-112.62
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.52
PB Ratio
3.22
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
73.02%
Net Margin
-22.48%
Revenue Growth (YoY)
5.56%
Profit Growth (YoY)
12.16%
3-Year Revenue Growth
-5.23%
3-Year Profit Growth
-3.09%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-112.62
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.52
PB Ratio
3.22
Price-to-FCF
-
Gross Margin
73.02%
Net Margin
-22.48%
Revenue Growth (YoY)
5.56%
Profit Growth (YoY)
12.16%
3-Year Revenue Growth
-5.23%
3-Year Profit Growth
-3.09%

  • When is BNR's latest earnings report released?

    The most recent financial report for Burning rock biotech limited (BNR) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BNR's short-term business performance and financial health. For the latest updates on BNR's earnings releases, visit this page regularly.

  • What is the operating profit of BNR?

    According to the latest financial report, Burning rock biotech limited (BNR) reported an Operating Profit of -16.13M with an Operating Margin of -12.26% this period, representing a growth of 58.2% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is BNR's revenue growth?

    In the latest financial report, Burning rock biotech limited (BNR) announced revenue of 131.62M, with a Year-Over-Year growth rate of 2.31%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does BNR have?

    As of the end of the reporting period, Burning rock biotech limited (BNR) had total debt of 33.18M, with a debt ratio of 0.04. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BNR have?

    At the end of the period, Burning rock biotech limited (BNR) held Total Cash and Cash Equivalents of 466.98M, accounting for 0.57 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does BNR go with three margins increasing?

    In the latest report, Burning rock biotech limited (BNR) did not achieve the “three margins increasing” benchmark, with a gross margin of 75.1%%, operating margin of -12.26%%, and net margin of -12.7%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BNR's profit trajectory and future growth potential.

  • Is BNR's EPS continuing to grow?

    According to the past four quarterly reports, Burning rock biotech limited (BNR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.6. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BNR?

    Burning rock biotech limited (BNR)'s Free Cash Flow (FCF) for the period is 16.39M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 154.14% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.